We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Informa Plc | LSE:INF | London | Ordinary Share | GB00BMJ6DW54 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.20 | 0.37% | 877.80 | 877.40 | 877.80 | 881.40 | 869.80 | 879.20 | 459,538 | 15:55:20 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Periodical:pubg,pubg & Print | 3.28B | 419M | 0.3150 | 27.83 | 11.63B |
Date | Subject | Author | Discuss |
---|---|---|---|
19/11/2024 11:49 | 4* Informa issued a 10-month trading update which confirmed more strong across the board performance. The Group reported double-digit underlying revenue growth across the first ten months of 2024 at a Group level (+10.7%), and in both B2B Markets (+11.1%) and Academic Markets (+10.0%). There was also growth in all major regions, underpinned by leading Brands and market positions in the Americas (c.45% of Group revenue), consistent growth... ...from WealthOracle wealthoracle.co.uk/d | martinmc123 | |
09/10/2024 17:36 | This is a cracker of a company | phillis | |
24/7/2024 06:34 | Yet another upgrade and offer for Ascential - which seems quite highly priced. But the management keep delivering - and they are highly incentivised to do so. It's beginning to throw up cash giving more room for investment in Ascential growth. | 18bt | |
08/5/2024 07:30 | Great update | phillis | |
07/5/2024 13:39 | no chat here? | phillis | |
08/3/2024 07:26 | They keep delivering.... | babbler | |
09/2/2024 12:54 | heavy into these breakthrough? | phillis | |
14/11/2023 08:35 | Keep posting. I'm sure there are other 'readers' like me... | charlock | |
14/11/2023 07:36 | Constantly amazed I am the only person on this thread. Yet another upgrade to INF forecasts, lots of detailed information for 2024 and increased capital returns. Forecast PER is only 16.x times and a realistic prospect of EPS growing more than 17% next year with similar sized dividend increases - i.e. a cheap compounder IMHO. Could even be cash positive within 3 years at current trajectory giving room for further acquisitions to enhance this. But I seem to be talking to myself .... | 18bt | |
27/7/2023 06:54 | First calcs - this could easily do 50p of EPS in 2024 - PER of under 15x looks v good value. Debt should come down very quickly, so they still have room for acquisitions which can add further value if they can keep pricing discipline. | 18bt | |
27/7/2023 06:41 | Strong interims with a statement that they will meet or beat full year forecasts.SP has been on a strong upward path for 9 months, but really happy to hold these. They appear to be guiding to at least £790m op profit - the consensus is around £773m , so some analysts are going to need to push up their forecasts. Recent acquisitions look v well timed and priced. In a very busy day for results, I need to look at further. | 18bt | |
15/6/2023 06:45 | Excellent news. This continues to be well managed. Not yet up to the July 2019 pre-COVID share price highs, but should begin to push there if growth continues. | 18bt | |
15/6/2023 06:25 | Very upbeat statement today - increasing 2023 guidance | nov31 | |
24/5/2023 13:36 | A very unpopular share - down today but generally up since Oct. 22 - anybody else watching this one? | mtness2 | |
09/3/2023 08:06 | Results look fine at first sight in line with or slightly beating consensus forecast. The Tarsus acquisition is interesting: -ve I don't like buying from private equity +ve significantly earnings enhancing as they look to have bought it v cheaply on under 10x 2023/24 forecast EBITDA The earnout only becomes payable when the Inf share price hits 850p i.e. 25% more than currently Mostly payable in cash and EBITDA prof forma leverage still only 1x Allowing quite a big share buy back beginning immediately Whilst consideration shares are subject to a 2 year lock up So buying in shares at around 700p and selling them at 850p looks clever. That looks a very strong deal, which the market seems to like at first sight | 18bt | |
19/1/2023 07:57 | Strong trading performance - seems to be beating mkt expectations and justifying the recent run-up in the share price | 18bt | |
14/11/2022 08:45 | under the radar | the white house | |
22/2/2022 11:00 | Been enjoying the recovery in these. Glad I kept my nerve in the Autumn sell-off. | 18bt | |
20/7/2021 13:55 | Having traded this profitably through 2020 I have reentered at 475. Whilst still a gamble on the direction of news it seems surprising to see it fall much under 500 with some recovery underway. The important Chinese market for B2B events is largely back to normal and the US is opening and should be generating much more revenue than in 2020. Only Europe (small for Informa) is lagging badly. The big health event in Shanghai in June drew over 70k attendees showing that scale events are back. The balance sheet and cash flow are fine. Underlying earnings should get back to prepandemic levels by 2023 (and possibly better given the cost clean up). Looks like a trading possibility again, but may need a bit of patience if the wider market falls. I will be interested to see the outlook statement with the half year results next week. | wba1 | |
07/7/2021 17:23 | what was all the interest yesterday | tony_penny | |
07/7/2021 17:23 | what was all the interest yesterday | tony_penny | |
09/11/2020 15:48 | seems to be the vaccine news which gives hope of a general opening up and possible resumption of exhibitions etc next year. | kenmill1 | |
09/11/2020 13:05 | What is going on? Up over 25% on the LSE website and Hargreaves has it at 484 to buy and 546 to sell ! - no announcement | kenmill1 | |
08/10/2020 01:03 | 12 years since the last post | smcni1968 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions